EP4301767A4 - Composés bioréactifs et leurs procédés d'utilisation - Google Patents
Composés bioréactifs et leurs procédés d'utilisationInfo
- Publication number
- EP4301767A4 EP4301767A4 EP22763916.8A EP22763916A EP4301767A4 EP 4301767 A4 EP4301767 A4 EP 4301767A4 EP 22763916 A EP22763916 A EP 22763916A EP 4301767 A4 EP4301767 A4 EP 4301767A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bioreactive
- compounds
- methods
- bioreactive compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C305/00—Esters of sulfuric acids
- C07C305/26—Halogenosulfates, i.e. monoesters of halogenosulfuric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/77—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/78—Halides of sulfonic acids
- C07C309/86—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/89—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
- C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C12Y601/01026—Pyrrolysine-tRNAPyl ligase (6.1.1.26)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163155222P | 2021-03-01 | 2021-03-01 | |
| US202163214432P | 2021-06-24 | 2021-06-24 | |
| PCT/US2022/018381 WO2022187273A1 (fr) | 2021-03-01 | 2022-03-01 | Composés bioréactifs et leurs procédés d'utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4301767A1 EP4301767A1 (fr) | 2024-01-10 |
| EP4301767A4 true EP4301767A4 (fr) | 2025-05-28 |
Family
ID=83154435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22763916.8A Pending EP4301767A4 (fr) | 2021-03-01 | 2022-03-01 | Composés bioréactifs et leurs procédés d'utilisation |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250283138A1 (fr) |
| EP (1) | EP4301767A4 (fr) |
| JP (1) | JP2024512297A (fr) |
| AU (1) | AU2022231099A1 (fr) |
| CA (1) | CA3212360A1 (fr) |
| WO (1) | WO2022187273A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022232377A2 (fr) * | 2021-04-28 | 2022-11-03 | The Regents Of The University Of California | Protéines bioréactives contenant des acides aminés non naturels |
| EP4452333A1 (fr) * | 2021-12-22 | 2024-10-30 | Enlaza Therapeutics, Inc. | Anticorps de réticulation |
| CN117003660B (zh) * | 2023-08-09 | 2026-03-27 | 四川大学 | 基于三氟甲基光脱氟-酰氟交换交联的非天然氨基酸及其用途 |
| CN121087130A (zh) * | 2025-11-12 | 2025-12-09 | 康码芯(上海)智能科技有限公司 | 一种用于插入非天然氨基酸的方法及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020072674A1 (fr) * | 2018-10-02 | 2020-04-09 | The Regents Of The University Of California | Agents de réticulation à cibles multiples et leurs utilisations |
| CN111302980A (zh) * | 2019-12-31 | 2020-06-19 | 上海交通大学医学院附属仁济医院 | 含硫酰氟基团的氨基酸类似物及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5590649B2 (ja) * | 2007-09-20 | 2014-09-17 | 独立行政法人理化学研究所 | 変異体ピロリジル−tRNA合成酵素及びこれを用いる非天然アミノ酸組み込みタンパク質の製造方法 |
| JP6738326B2 (ja) * | 2014-06-06 | 2020-08-12 | ザ スクリプス リサーチ インスティテュート | フッ化硫黄(vi)化合物およびそれの製造方法 |
| EP3845661A4 (fr) * | 2018-08-31 | 2022-06-22 | Riken | Pyrrolysyl-arnt synthétase |
-
2022
- 2022-03-01 WO PCT/US2022/018381 patent/WO2022187273A1/fr not_active Ceased
- 2022-03-01 US US18/279,463 patent/US20250283138A1/en active Pending
- 2022-03-01 JP JP2023553044A patent/JP2024512297A/ja active Pending
- 2022-03-01 CA CA3212360A patent/CA3212360A1/fr active Pending
- 2022-03-01 AU AU2022231099A patent/AU2022231099A1/en active Pending
- 2022-03-01 EP EP22763916.8A patent/EP4301767A4/fr active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020072674A1 (fr) * | 2018-10-02 | 2020-04-09 | The Regents Of The University Of California | Agents de réticulation à cibles multiples et leurs utilisations |
| CN111302980A (zh) * | 2019-12-31 | 2020-06-19 | 上海交通大学医学院附属仁济医院 | 含硫酰氟基团的氨基酸类似物及其制备方法和应用 |
Non-Patent Citations (3)
| Title |
|---|
| GAMBINI LUCA ET AL: "Covalent Inhibitors of Protein-Protein Interactions Targeting Lysine, Tyrosine, or Histidine Residues", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 11, 13 June 2019 (2019-06-13), US, pages 5616 - 5627, XP055898707, ISSN: 0022-2623, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00561> DOI: 10.1021/acs.jmedchem.9b00561 * |
| See also references of WO2022187273A1 * |
| WANG NANXI ET AL: "Genetically Encoding Fluorosulfate-l-tyrosine To React with Lysine, Histidine, and Tyrosine via SuFEx in Proteins in Vivo", LANGMUIR, vol. 140, no. 15, 30 March 2018 (2018-03-30), pages 4995 - 4999, XP055816028, Retrieved from the Internet <URL:https://pubs.acs.org/doi/abs/10.1021/jacs.8b01087> DOI: 10.1021/jacs.8b01087 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3212360A1 (fr) | 2022-09-09 |
| AU2022231099A1 (en) | 2023-08-31 |
| US20250283138A1 (en) | 2025-09-11 |
| EP4301767A1 (fr) | 2024-01-10 |
| JP2024512297A (ja) | 2024-03-19 |
| WO2022187273A1 (fr) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4329757A4 (fr) | Composés hétérocycliques et procédés d'utilisation | |
| EP4301767A4 (fr) | Composés bioréactifs et leurs procédés d'utilisation | |
| EP4291201A4 (fr) | Composés, compositions et leurs méthodes d'utilisation | |
| EP4037695A4 (fr) | Compositions oligonucléotidiques et leurs procédés d'utilisation | |
| EP3958872A4 (fr) | Compositions d'oligonucléotides et leurs procédés d'utilisation | |
| EP3968999A4 (fr) | Inhibiteurs de fgfr et leurs procédés d'utilisation | |
| EP3790596A4 (fr) | Compositions d'oligonucléotides et leurs procédés d'utilisation | |
| EP3775203A4 (fr) | Compositions d'oligonucléotides et leurs procédés d'utilisation | |
| MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
| MA56032A (fr) | Composés, compositions et procédés d'utilisation | |
| MA54538A (fr) | Inhibiteurs d'apol1 et leurs procédés d'utilisation | |
| EP3941459A4 (fr) | Composés de quinoléine et de quinazoline et leurs procédés d'utilisation | |
| MA55381A (fr) | Pyridazinones et leurs procédés d'utilisation | |
| EP3893917A4 (fr) | Compositions d'il-15 et leurs procédés d'utilisation | |
| EP2152256A4 (fr) | Composés activant la télomérase et leurs procédés d'utilisation | |
| EP4211233A4 (fr) | Compositions et leurs procédés d'utilisation | |
| EP3886854A4 (fr) | Composés pyrrole et pyrazole et leurs procédés d'utilisation | |
| MA56457A (fr) | Modulateurs de hsd17b13 et leurs procédés d'utilisation | |
| MA71645A (fr) | Pyridazinones et leurs procédés d'utilisation | |
| EP4319813A4 (fr) | Multimères de peptide-mhc-immunoglobuline et leurs procédés d'utilisation | |
| EP4329521A4 (fr) | Compositions de collagène et leurs procédés d'utilisation | |
| MA55532A (fr) | Composés de neuréguline-4 et procédés d'utilisation | |
| EP3965776A4 (fr) | Compositions oligosaccharidiques et leurs procédés d'utilisation | |
| EP4048402A4 (fr) | Lymphocytes t cytoxiques modifiés et leurs procédés d'utilisation | |
| EP4346815A4 (fr) | Composés hétérocycliques et procédés d'utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230921 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40106152 Country of ref document: HK |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C07K0001107000 Ipc: A61K0047640000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20250428 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/50 20060101ALI20250422BHEP Ipc: G01N 30/72 20060101ALI20250422BHEP Ipc: C12P 21/02 20060101ALI20250422BHEP Ipc: C07K 1/107 20060101ALI20250422BHEP Ipc: A61K 47/68 20170101ALI20250422BHEP Ipc: A61K 47/64 20170101AFI20250422BHEP |